In a report released today, Chris Shibutani from Cowen & Co. maintained a Buy rating on Kura Oncology (KURA). The company’s shares opened today at $14.86.
According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 4.7% and a 47.6% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Five Prime Therapeutics, Nektar Therapeutics, and United Therapeutics.
Kura Oncology has an analyst consensus of Moderate Buy, with a price target consensus of $29.50, a 98.5% upside from current levels. In a report released yesterday, Oppenheimer also assigned a Buy rating to the stock with a $28 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $23.35 and a one-year low of $10.20. Currently, Kura Oncology has an average volume of 235.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.
